Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

David A. Evans, A. Mahgoub, T.P. Sloan et al. · Journal of Medical Genetics · 1980 · 540 citations · Full text

Life Sciences, Genetics, Pharmacology +17

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

Kōichi Nakamura, Fumio Goto, Wayne A. Ray et al. · Clinical Pharmacology & Therapeutics · 1985 · 457 citations

Pharmacy, Pharmacology, Toxicology +14

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

Lyle A. Siddoway, Katherine A. Thompson, C B McAllister et al. · Circulation · 1987 · 274 citations

Medicine, Pharmacokinetics, Pharmacology +14

Clinical pharmacology of propafenone.

Stuart J. Connolly, Robert E. Kates, Cynthia Lebsack et al. · Circulation · 1983 · 183 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

Eugen Steiner, Lennart Iselius, Gunnar Alván et al. · Clinical Pharmacology & Therapeutics · 1985 · 126 citations

Life Sciences, Genetics, Pharmacology +17